Mereo BioPharma Group plc (NASDAQ:MREO) is trading at $0.49 with a target price of $2.14, indicating a potential growth of approximately 333.27%.ProQR Therapeutics N.V. (PRQR) has a target price more than 50% below its current market price, reflecting a negative growth potential of -51.43%.Investing in biopharmaceutical companies like Mereo BioPharma requires understanding the clinical trial process and the potential for product approval due to inherent risks.Mereo BioPharma Group plc (NASDAQ:MREO) is a bio ...